<DOC>
	<DOCNO>NCT00455767</DOCNO>
	<brief_summary>The study aim assess safety Depelestat treatment , well efficacy prevention treatment alveolar inflammation early pulmonary fibrosis patient suffer persistent Acute Respiratory Distress Syndrome .</brief_summary>
	<brief_title>Safety Efficacy Study Depelestat Acute Respiratory Distress Syndrome ( ARDS ) Patients</brief_title>
	<detailed_description>This multicenter , randomise , double-blind , parallel group , placebo-controlled , 1 week treatment Depelestat , patient suffer persistent ARDS . Patients admit intensive care unit presenting ARDS criterion persistent 12 hour 24 hour , randomly assign treatment Depelestat placebo , pre-treatment period short possible maximum 48 hour since ARDS criterion meet . During pre-treatment period , informed consent obtain legally authorize relative patient , pre-treatment biological functional examination perform , particularly blood sample BAL biological parameter measurement , ventilatory mechanic , assessment static compliance respiratory system . After pre-treatment period , patient receive treatment Depelestat placebo 7 day , extubation patient occur 7 day treatment . During treatment period , patient submit daily measurement static compliance respiratory system , long patient adaptation 24 hour mechanical ventilation allow procedure , 96 initiation treatment , blood sample bronchoalveolar lavage several biological parameter assessment . On first last day administration , blood also collect pharmacokinetic evaluation . During post-treatment period , patient submit , 48 h Â± 24 h end treatment , blood sample BAL ( BAL perform contraindication criterion present , patient already extubated , case plan extubation subsequent 24 hour ) several biological parameter assessment , daily measurement static compliance long patient adaptation mechanical ventilation allow procedure . Patients already extubated submit BAL static compliance measurement . After end treatment , patient follow daily 28 day diagnostic ARDS , death whichever occur first . The duration study survivor patient 28 day . Survivors day 28 contact monthly ass survival fill QOL questionnaire day 60 90 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<criteria>Patients suffer persistent ARDS define American European Consensus Conference ARDS , 1994 ARDS secondary traumatism Pulmonary emphysema pulmonary fibrosis Lung pneumocystosis Bronchopleural fistula Systemic corticosteroid treatment 2 week inclusion Severe organ disease except renal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>persistent ARDS</keyword>
	<keyword>alveolar inflammation</keyword>
	<keyword>early pulmonary fibrosis</keyword>
	<keyword>mechanichal ventilation</keyword>
	<keyword>P/V curve</keyword>
	<keyword>Static compliance</keyword>
	<keyword>elastase activity</keyword>
	<keyword>inhibitor Human Neutrophil Elastase</keyword>
</DOC>